In previous studies evaluating the NGAL levels in patients with hematological malignancies, the samples examined were mostly peripheral blood (PB).5, 6, 7 Although a previous study was conducted using human bone marrow (BM) samples, the only disease entity examined in that study was acute myeloid leukemia (AML).9 This evidence concerns the gene LCN2 and acute myeloid leukemia.